Page 15 - Pharma Companies

Aurobindo Pharma recalls Mirtazapine tablets in US over label error

The product is being recalled due to a label error on declared strength

NCLT dissolves Orchid Pharma's promoter firm, says no gain for shareholders

CoC says parent firm has no assets other than holding in Orchid Pharma, which itself is undergoing CIRP; Even if there is a resolution for Orchid Pharma, nothing would be left for investors

Dr Reddy's gives part manufacturing to China partners to tap local market

The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's

Exposure to US market causing constant FDA scrutiny for big drug firms

Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator

Regulatory woes resurface for Indian pharma companies as stocks fall

Concerns over US sales are diluting positives of strong domestic growth, and have led to a 10 per cent fall in the Nifty Pharma index in one month

FDA observations on Telangana plant a fresh headache for Aurobindo Pharma

The Telangana unit in question is an important one contributing about a fifth to US revenues

India's leading drugmakers stocking up to avoid supply disruptions

Have increased raw material buffer stock by at least 40 days in recent months

Apollo Hospitals to seek shareholders' nod for hiving off pharmacy biz

Front end of the business to go to a separate firm, which will focus on achieving Rs 10,000 cr revenue and 30% ROCE within 5 years

300 fresh pharma unit applications up for approval in Gujarat: FDCA

As per the state FDCA commissioner, the state has benefited from the introduction of GST

Aurobindo Pharma gains nearly 8% on growth prospects in US market

The completion of Sandoz acquisition and new product launches are triggers

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets

Cipla urges govt to increase funds, ease policies for domestic pharma firms

In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health

Growth in US business likely to boost Q1 revenues of pharma companies

According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY

Centre may get stricter to check overcharging of medicines by pharma cos

The idea is to cancel the licenses of manufacturers who do not deposit the demanded amount within the prescribed time limit given by the NPPA

Domestic-focused pharma companies gain spotlight with stable growth outlook

Those with high non-US revenue streams such as Torrent Pharma, Ipca Labs, Ajanta Pharma and a few multinationals remain well placed

US drag on pharma majors' margins in Q4; experts see R&D costs rising

While the US headwinds continue, domestic market sales have been positive and show signs of recovery after the implementation of the goods and services tax

From Cipla to Glenmark, pharma companies' double-digit growth in doubt

Govt's proposed changes in pricing policy could play spoilsport

Eight Chinese pharma firms may get blacklisted over low quality materials

The notices were issued after a special inspection team of the Drug Controller General of India inspected the eight companies in China

Pharma companies' revenues seen growing at 9% over next 3 years: Crisil

Exports, which account for nearly 45 per cent of industry revenue, will see another year of a tepid one per cent growth in fiscal 2018

Revival of US generic sales not before FY19, say analysts

Sharp fall in Teva's June quarter earnings dash hopes of recovery for domestic pharma firms